These cytokines were profiled longitudinally in 98 melanoma patients receiving mono-immunotherapy with anti-PD-1 and validated on 49 patients receiving combo immunotherapy with anti-PD-1 and anti-CTLA-4. This evidence concerns the gene CTLA4 and melanoma.